Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Simple item page
dc.contributor.authorKahraman S.
dc.contributor.authorErul E.
dc.contributor.authorSeyyar M.
dc.contributor.authorGumusay O.
dc.contributor.authorBayram E.
dc.contributor.authorDemirel B.C.
dc.contributor.authorAcar O.
dc.contributor.authorAksoy S.
dc.contributor.authorBaytemur N.K.
dc.contributor.authorSahin E.
dc.contributor.authorCabuk D.
dc.contributor.authorBasaran G.
dc.contributor.authorPaydas S.
dc.contributor.authorYaren A.
dc.contributor.authorGuven D.C.
dc.contributor.authorErdogan A.P.
dc.contributor.authorDemirci U.
dc.contributor.authorYasar A.
dc.contributor.authorBayoglu İ.V.
dc.contributor.authorHizal M.
dc.contributor.authorGulbagci B.
dc.contributor.authorPaksoy N.
dc.contributor.authorDavarci S.E.
dc.contributor.authorYilmaz F.
dc.contributor.authorDogan O.
dc.contributor.authorOrhan S.O.
dc.contributor.authorKayikcioglu E.
dc.contributor.authorAytac A.
dc.contributor.authorKeskinkilic M.
dc.contributor.authorMocan E.E.
dc.contributor.authorUnal O.U.
dc.contributor.authorAydin E.
dc.contributor.authorYucel H.
dc.contributor.authorIsik D.
dc.contributor.authorEren O.
dc.contributor.authorUluc B.O.
dc.contributor.authorOzcelik M.
dc.contributor.authorHacibekiroglu I.
dc.contributor.authorAydiner A.
dc.contributor.authorDemir H.
dc.contributor.authorOksuzoglu B.
dc.contributor.authorCilbir E.
dc.contributor.authorCubukcu E.
dc.contributor.authorCetin B.
dc.contributor.authorOktay E.
dc.contributor.authorErol C.
dc.contributor.authorOkutur S.K.
dc.contributor.authorYildirim N.
dc.contributor.authorAlkan A.
dc.contributor.authorSelcukbiricik F.
dc.contributor.authorAksoy A.
dc.contributor.authorKarakas Y.
dc.contributor.authorOzkanli G.
dc.contributor.authorDuman B.B.
dc.contributor.authorAydin D.
dc.contributor.authorDulgar O.
dc.contributor.authorEr M.M.
dc.contributor.authorTeker F.
dc.contributor.authorYavuzsen T.
dc.contributor.authorAykan M.B.
dc.contributor.authorInal A.
dc.contributor.authorIriagac Y.
dc.contributor.authorKalkan N.O.
dc.contributor.authorKeser M.
dc.contributor.authorSakalar T.
dc.contributor.authorMenekse S.
dc.contributor.authorKut E.
dc.contributor.authorBilgin B.
dc.contributor.authorKaraoglanoglu M.
dc.contributor.authorSunar V.
dc.contributor.authorOzdemir O.
dc.contributor.authorTurhal N.S.
dc.contributor.authorKaradurmus N.
dc.contributor.authorYalcin B.
dc.contributor.authorNahit Sendur M.A.
dc.date.accessioned2024-07-22T08:03:09Z
dc.date.available2024-07-22T08:03:09Z
dc.date.issued2023
dc.description.abstractBackground: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference. © 2023 Future Medicine Ltd.
dc.identifier.DOI-ID10.2217/fon-2022-1287
dc.identifier.issn14796694
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12153
dc.language.isoEnglish
dc.publisherNewlands Press Ltd
dc.subjectAminopyridines
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectBreast Neoplasms
dc.subjectFemale
dc.subjectHumans
dc.subjectLetrozole
dc.subjectReceptor, ErbB-2
dc.subjectRetrospective Studies
dc.subjectTreatment Outcome
dc.subjectepidermal growth factor receptor 2
dc.subjectestrogen receptor
dc.subjectletrozole
dc.subjectpalbociclib
dc.subjectprogesterone receptor
dc.subjectribociclib
dc.subjectaminopyridine derivative
dc.subjectantineoplastic agent
dc.subjectepidermal growth factor receptor 2
dc.subjectletrozole
dc.subjectpalbociclib
dc.subjectribociclib
dc.subjectadult
dc.subjectaged
dc.subjectanemia
dc.subjectArticle
dc.subjectclinical feature
dc.subjectcohort analysis
dc.subjectcontrolled study
dc.subjectdrug dose reduction
dc.subjectdrug efficacy
dc.subjectdrug preference
dc.subjectdrug withdrawal
dc.subjectestrogen receptor-positive, HER2-negative breast cancer
dc.subjectfebrile neutropenia
dc.subjectfemale
dc.subjecthormone receptor-positive, HER2-negative breast cancer
dc.subjecthormone sensitivity
dc.subjecthuman
dc.subjecthypertransaminasemia
dc.subjectliver toxicity
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectneutropenia
dc.subjectoverall survival
dc.subjectprogesterone receptor positive breast cancer
dc.subjectprogression free survival
dc.subjectretrospective study
dc.subjectthrombocytopenia
dc.subjectbreast tumor
dc.subjectpathology
dc.subjecttreatment outcome
dc.titleTreatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
dc.typeArticle

Files

Collections

Scopus Koleksiyonu